AlphaSolid®100 genetic tumour test
A highly sensitive tissue biopsy test analysing 118 cancer-related genes, helping select the most precise treatment strategy for patients with solid tumours.
Precise treatment starts with genetic tumour analysis
Successful treatment of solid tumours depends on the ability to apply individualised therapy. Standard testing often does not reveal all the necessary information about a tumour’s genetic characteristics.
AlphaSolid®100 analyses 118 cancer-related genes, accurately defines the tumour’s genomic profile, and supports evidence-based decisions for a personalised treatment plan.
What does the AlphaSolid®100 genetic test determine?
AlphaSolid®100 is an advanced biopsy-based test that profiles the genetics of solid tumours. The test uses a tumour tissue sample and, with UniqSeq® technology and next-generation sequencing (NGS), identifies key genetic alterations affecting disease course and treatment response. It helps answer questions such as:
Which genetic alterations drive the growth and resistance of a particular tumour?
Does the tumour have actionable targets for targeted therapy or immunotherapy?
What is the tumour’s molecular subtype and its prognostic significance?
Should additional monitoring with liquid biopsy tests (e.g., AlphaLiquid®100) be considered during treatment?
Personalised treatment: when decisions are guided by tumour genetics
AlphaSolid®100 helps clinicians make evidence-based decisions grounded in the tumour’s genetic profile. Results support more accurate diagnosis, individualised treatment planning, and more effective monitoring of disease course or relapse risk.
Precise therapy selection
Identifies actionable genetic targets that can guide targeted therapy or immunotherapy, helping achieve better treatment outcomes.
Individualised treatment plan
Tumour genetic information helps avoid ineffective therapy and reduces the risk of side effects.
Monitoring progression and relapse
Based on the tumour profile, clinicians can plan follow-up liquid biopsy testing (e.g., AlphaLiquid®100) to detect genetic changes and early signs of relapse in time.
Broader molecular insight
Covers 118 clinically relevant genes, providing a comprehensive tumour profile even in complex cases.
When and for whom is the test recommended?
For patients diagnosed with a solid tumour who have not yet started treatment
Helps select a targeted, genetically informed treatment strategy from the outset.
For patients receiving standard oncology therapy
Enables evaluation of whether current treatment aligns with the tumour’s molecular profile and whether therapy adjustment is needed.
For patients with recurrent or progressing disease
Provides insight into new genetic alterations associated with treatment resistance or relapse.
For patients for whom single-gene testing is insufficient
AlphaSolid®100 analyses 118 clinically relevant genes – especially useful when comprehensive molecular profiling is required.
AlphaSolid®100 reliability: accuracy and quality metrics
The test uses patented UniqSeq® technology and next-generation sequencing (NGS) to accurately identify genetic alterations in tumour tissue – providing a reliable basis for personalised treatment.
Analysis of 118 oncology-related genes
Validated UniqSeq® technology – a foundation of clinical reliability
A genetically informed treatment plan
Take the AlphaSolid®100 test and receive a comprehensive tumour genetic profile to guide personalised treatment.
For Specialists
All key information in one place – from the genes analysed to test accuracy and clinical value. This section is intended for specialists who want a detailed understanding of the test rationale, structure, and practical applications.
AlphaSolid®100 is a comprehensive solid tumour tissue biopsy test designed to determine the tumour’s genomic profile and support treatment individualisation based on tumour genotype. The analysis covers 118 clinically relevant genes, including 34 drug targets, 15 HRR genes, and 10 gene fusions.
The test is performed using targeted hybrid-capture next-generation sequencing (NGS) based on patented HQS™ technology. Panel size: 466 kb.
Sensitivity and accuracy are supported by 50,000× sequencing depth and 8,000×+ unique molecule coverage. Results show 90–95% concordance with tumour tissue genetic findings. Performance is supported by analysis of 10,000+ clinical samples.
AlphaSolid®100 can detect:
- Single-nucleotide variants (SNVs)
- Insertions and deletions (InDels)
- Copy number alterations (CNAs)
- Gene fusions
- Homologous recombination repair (HRR) gene alterations
The test reports two important molecular biomarkers: microsatellite instability (MSI) and tumour mutational burden (TMB).
